Linaprazan

Cat. No.: HY-100412
CAS No.: 248919-64-4
Molecular Formula: C_{21}H_{26}N_{4}O_{2}
Molecular Weight: 366.46
Target: Proton Pump
Pathway: Membrane Transporter/Ion Channel
Storage:
- Powder: -20°C, 3 years; 4°C, 2 years
- In solvent: -80°C, 6 months; -20°C, 1 month

Solvent & Solubility

In Vitro
DMSO: ≥ 35 mg/mL (95.51 mM)
*“≥” means soluble, but saturation unknown.

<table>
<thead>
<tr>
<th>Preparing Stock Solutions</th>
<th>Concentration</th>
<th>1 mg</th>
<th>5 mg</th>
<th>10 mg</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>1 mM</td>
<td>2.7288 mL</td>
<td>13.6441 mL</td>
<td>27.2881 mL</td>
</tr>
<tr>
<td></td>
<td>5 mM</td>
<td>0.5458 mL</td>
<td>2.7288 mL</td>
<td>5.4576 mL</td>
</tr>
<tr>
<td></td>
<td>10 mM</td>
<td>0.2729 mL</td>
<td>1.3644 mL</td>
<td>2.7288 mL</td>
</tr>
</tbody>
</table>

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description
AZD0865 inhibits gastric H+,K+-ATPase by K+-competitive binding. (IC50: 1.0 ± 0.2 μM) It is an acid-suppressing agents with rapid onset of action and potent acid inhibition. In vitro: AZD0865 can inhibit the final step in acid secretion. AZD0865 reduced porcine renal Na+,K+-ATPase activity by 9 ± 2%, demonstrating a high selectivity for H+,K+-ATPase. In vivo: The reference for animal administration is 0.5-1.0 mg/kg. The greater degree of acid suppression with the 75-mg dose of AZD0865 would translate to a healing rate of 89% at 4 weeks.

REFERENCES

